18F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 6, 2015, Pages

  Smailagic, Nadja ^a   Vacante, Marco ^b   Hyde, Chris ^c   Martin, Steven ^a   Ukoumunne, Obioha ^c   Sachpekidis, Christos ^d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^d Aristotle University and Hippokration General Hospital   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE 18; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ALZHEIMER DISEASE; BRAIN REGION; CEREBROSPINAL FLUID; DEMENTIA; DIAGNOSTIC ACCURACY; DIFFUSE LEWY BODY DISEASE; EARLY DIAGNOSIS; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); VALIDITY; AGED; BRAIN; COGNITIVE DEFECT; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE COURSE; META ANALYSIS; MIDDLE AGED;

AGED; ALZHEIMER DISEASE; BRAIN; COGNITIVE DYSFUNCTION; DEMENTIA; DISEASE PROGRESSION; EARLY DIAGNOSIS; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 85017364549     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010632.pub2     Document Type: Review

References (130)

1. Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, Kerrouche N, at al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Archives of Neurology 2005;62(11):1728-33.
2. Arnáiz E, Jelic V, Almkvist O, Wahlund L-O, Winbald B, Valind S, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 2001;12(4):851-5.
3. Berent S, Giordani B, Foster N, Minoshima S, Lajiness-O'Neill R, Koeppe R, et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. Journal of Psychiatric Research 1999;33(1):7-16.
4. Chételat G, Desgranges B, De la Sayette V, Viadre F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology 2003;60(8):1374-7.
5. Clerici F. Differences in hippocampal metabolism between amnestic and non-amnestic MCI subjects: automated FDG-PET image analysis. Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009;53(6):646-57.
6. Drzezga A, Grimmer T, Rimenschneider M, Lautenschlager N, Siebner H, Alexopoulus, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. Journal of Nuclear Medicine 2005;46(10):1625-32.
7. Fellgiebel A, Scheurich A, Bartenstein P, Müller MJ. FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Research 2007;155(2):167-71.
8. Galluzzi S, Geroldi, C, Ghidoni R, Paghera B, Amicucci B, Bonetti M, et al. The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology 2010;257(12):2004-14.
9. Herholz K, Westwood S, Haense C, Dunn G. Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. Journal of Nuclear Medicine 2011;52(8):1218-26.
10. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010;75(3):230-8.
11. Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, et al. MCI conversion to dementia and APOE genotype: a prediction study with FDG-PET. Neurology 2004;63(12):2332-40.
12. Nobili F, Salmaso D, Morbelli S, Girtler N, Piccardo A, Brugnolo A, et al. Principal component analysis of FDG PET in amnestic MCI. European Journal of Nuclear Medicine and Molecular Imaging 2008;35(12):2191-202.
13. Ossenkoppele R, Tolboom N, Foster-Dingley JC, Adriaanse SF, Boellaard R, Yaqub M, et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging 2012;39(6):990-1000.
14. Ossenkoppele R, Prins N, Pijnenburg YAL, Lemstra AW, Van der Flier WM, Adriaanse SF, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's & Dementia 2012;9(4):414-21.
15. Pardo JV, Lee JT, Kuskowski MA, Munch KR, Carlis JV, Sheikh SA, et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow-up at 3 years. Alzheimer's & Dementia 2010;6(4):326-33.
16. Schmand B, Eikelenboom P, van Gool WA, Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer's Disease in young and old patients with amnestic mild cognitive impairment. Journal of Alzheimer's Disease 2012;29(3):641-8.
17. Bastin C, Kerrouche N, Lekeu F, Adam S, Guillame B, Lemaire C, et al. Controlled memory processes in questionable Alzheimer's disease: A view from neuroimaging research. Journal of Alzheimer's Disease 2010; Vol. 20, issue 2:547-60.
18. Beckett LA, Harvey DJ, Gamst A, Donohue M, Kornak J, Zhang H, et al. The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimer's & Dementia 2010; Vol. 6, issue 3:257-64. [1552-5260]
19. Charil A, Carbonell F, Reilhac A, Deduck K, Sood R, Evans A. Changes in MRI cortical thickness and [18F]FDG PET data over 24 months in subjects from the Alzheimer's disease neuroimaging initiative (ADNI) study. Alzheimer's and Dementia Conference: Alzheimer's Association International Conference, AAIC 11 Paris France. Conference Publication. 2011.
20. Chen K, Langbaum JB, Fleisher AS, Ayutyanont N, Reschke C, Lee W, et al. Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative. NeuroImage 2010; Vol. 51, issue 2:654-64. [1053-8119]
21. Chételat G, Desgranges B, De la Sayette V, Lalevee C, Landeau B, Dupuy B. Metabolic profile of patients with mild cognitive impairment (MCI) destined to convert to Alzheimer's disease (AD). Society for Neuroscience Abstracts 2001;27(1):196.
22. Chételat G, Eustache F, Viader F, De la Sayette V, Pélerin A, Mézenge F, et al. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase 2005; Vol. 11, issue 1:14-25.
23. Desikan RS, Cabral HJ, Settecase F, Hess CP, Dillon WP, Glastonbury CM, et al. Automated MRI measures predict progression to Alzheimer's disease. Neurobiology of Aging 2010; Vol. 31, issue 8:1364-74.
24. Drzezga A, Lautenschlager N, Siebner H, Reimenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. European Journal of Nuclear Medicine and Molecular Imaging 2003;30(8):1104-13.
25. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiology of Aging 2008; Vol. 29, issue 10:1456-65.
26. Garibotto V, Borroni B, Kalbe E, Herholz K, Salmon E, Holtoff V, et al. Education and occupation as proxies for reserve in aMCI converters and AD FDG-PET evidence. Neurology 2008;71(17):1342-9.
27. Gray KR, Wolz R, Heckemann RA, Aljabar P, Hammers A, Rueckert D. Multi-region analysis of longitudinal FDG-PET for the classification of Alzheimer's disease. NeuroImage 2012;60(1):221-9.
28. Hunt A, Schönknecht P, Henze M, Seidl U, Haberkorn U, Schröder J. Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease. Psychiatry Research 2007;155(2):147-54.
29. Ishii H, Ishikawa H, Meguro K, Tashiro M, Yamaguchi S. Decreased cortical glucose metabolism in converters from CDR 0.5 to Alzheimer's disease in a community: the Osaki-Tajiri Project. International Psychogeriatrics 2009;21(1):148-56.
30. Ishii K, Ito K, Senda M, Kato T, Fukuyama H, Ouchi Y, Meguro K, et al. SEAD-J Group. FDG-PET and automatic diagnosis systems for prediction of conversion to Alzheimer disease in subjects with mild cognitive impairments: Study on diagnosis of early Alzheimer disease-Japan (SEAD-J). Annual Congress of the European Association of Nuclear Medicine, Birmingham. Conference Publication. 2011.
31. Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?. Neurology 2007;69(9):871-7.
32. Kadir A, Almkvist O, Forsberg A, Wall A, Engler H, Langstrom B, Nordberg A. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiology of Aging 2012;33(1):198.e1-14.
33. Kawashima S, Ito K, Kato T, SEAD-J Study Group. Inclusion criteria provide heterogeneity in baseline profiles of patients with mild cognitive impairment: comparison of two prospective cohort studies. BMJ Open 2012;2(2):e000773.
34. Kim SK, Seo SW, Yoon DS, Chin J, Lee BH, Cheong HK, et al. Comparison of neuropsychological and FDG-PET findings between early- versus late-onset mild cognitive impairment: A five-year longitudinal study. Dementia and Geriatric Cognitive Disorders 2010;29(3):213-23.
35. Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, Weiner MW, Jagust WJ, the Alzheimer's Disease Neuroimaging Initiative. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MC. Neurobiology of Aging 2011;32(7):1207-18.
36. Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, at al, Alzheimer's Disease Neuroimaging Initiative. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Annals of Neurology 2012;72(4):578-86.
37. Lee DY, Choo LLH, Seo EH, Sohn BK, Park JH, Kim JW, et al. Combination of cerebral metabolic and cognitive information as a better predictor of the conversion to Alzheimer's disease in mild cognitive impairment: A two-year follow-up study. Alzheimer's & Dementia 2011;7(4 Supplement):S29.
38. Lo RY, Hubbard AlE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS. Longitudinal change of biomarkers in cognitive decline. Archives of Neurology 2011;68(10):1257-66.
39. Lo RY, Jagust W. Vascular burden and Alzheimer disease pathologic progression. Neurology 2012;79(13):1349-55.
40. Lorenzi M, Donohue M, Paternico D, Scarpazza C, Ostrowictzki S, Blin O, et al. Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment. Neurobiology 2010;31(8):1443-51.
41. Lucidi G, Marini S, Nacmias B, Berti V, Bessi V, Bracco L et al. Journal of Alzheimer's Disease Conference: 7th Congresso Sindem: Italian Association for the Study of Dementia Linked to the Italian Neurological Society, SIN Naples Italy. Multidisciplinary approach to MCI help to evaluate risk of conversion in AD. Journal of Alzheimer's Disease Conference: 7th Congresso Sindem: Italian Association for the Study of Dementia Linked to the Italian Neurological Society, SIN Naples Italy. 2012:(var.pagings).
42. Morbelli S, Piccardo A, Villavecchia G, Dessi B, Brugnolo A, Piccini A, et al. Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. European Journal of Nuclear Medicine and Molecular Imaging 2010;37(1):36-45. [1619-7070]
43. Morbelli S, Drzezga A, Perneczky R, Frisoni GB, Caroli A, Van Berckel BNM, et al. Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project. Neurobiology of Aging 2012;33(11):2533-50.
44. Pagani M, Dessi B, Morbelli S, Brugnolo A, Salmaso D, Piccini A. MCI patients declining and not-declining at mid-term follow-up: FDG-PET findings. Current Alzheimer Research 2010;7(4):287-94.
45. Small GW, La Rue A, Komo S, Kaplan A, Mandelkern MA. Predictors of cognitive change in middle-aged and older adults with memory loss. American Journal of Psychiatry 1995;152(12):1757-64.
46. Torosyan N, Mason K, Dahlbom M, Silverman DH. Predictive value of FDG-PET scans for conversion from mild cognitive impairment to dementia by subjects participating in the Alzheimer's Disease Neuroimaging Initiative study, using a metabolic index generated with clinically routine software. Molecular Imaging and Biology Conference: 2011 World Molecular Imaging Congres, San Diego, CA United States. Conference Publication. 2011.
47. Walhovd KB, Fjell AM, Brewer J, McEvoy LK, Fennema-Notestine C, Hagler DJ, et al. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR: American Journal of Neuroradiology 2010;31(2):347-54.
48. Zhang D, Shen D. Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers. PLoS One 2012;7(3):e33182.
49. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011;7(3):270-9. [1552-5260]
50. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R). 3rd Edition. Washington DC: American Psychiatric Association, 1987.
51. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). 4th Edition. Washington DC: American Psychiatric Association, 1994.
52. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011;377(9770):1019-31. [PUBMED: 21371747]
53. Bartenstein P, Minoshima S, Hirsch C, Buch K, Willoch F, Mösch D, et al. Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT. Journal of Nuclear Medicine 1997;38(7):1095-101.
54. Bartenstein P, Asenbaum S, Catafau A, Halldin C, Pilowski L, Pupi A, et al. European Association of Nuclear Medicine procedure guidelines for brain imaging using [18F]FDG. European Journal of Nuclear Medicine and Molecular Imaging 2002;29(10):BP43-8.
55. Beynon R, Leeflang MM, McDonald S, Eisinga A, Mitchell RL, Whiting P, et al. Search strategies to identify diagnostic accuracy studies in MEDLINE and EMBASE. Cochrane Database of Systematic Reviews 2013, Issue 9. [DOI: 10.1002/14651858.MR000022.pub3]
56. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI:10.1002/14651858.MR000022.pub3 ]
57. Bohnen NI, Djang DSW, Herholz K, Anzai Y, Minoshima S. Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. Journal of Nuclear Medicine 2012;53(1):59-71.
58. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Family Practice 2004;21(1):4-10. [0263-2136]
59. Bossuyt PM, Leeflang MM. Developing criteria for including studies. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Chapter 6. Version 0.4. srdta.cochrane.org/sites/srdta.cochrane.org/files/uploads/Chapter06-Including-Studies%20%28September-2008%29.pdf 2008.
60. Boxer AL, Miller BL. Clinical features of frontotemporal dementia. Alzheimer Disease and Associated Disorders 2005; Vol. 19, issue Suppl 1:S3-6. [0893-0341]
61. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica 1991; Vol. 82, issue 4:239-59. [0001-6322]
62. Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. International Psychogeriatrics 2004; Vol. 16, issue 2:129-40. [1041-6102]
63. Brück A, Virta JR, Koivunen J, Koikkalainen J, Scheinin NM, Helenius H, et al. [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment. European Journal of Nuclear Medicine and Molecular Imaging 2013;40(10):1567-72.
64. Catana C, Drzezga A, Heiss WD, Rosen BR. PET/MRI for neurologic applications. Journal of Nuclear Medicine 2012;53(12):1916-25.
65. Crook T, Bartus RT, Ferris SH, Whitehouse P, Cohen GD, Gershon S. Report of a National Institute of Mental Health Work Group: Age associated memory impairment: proposed diagnostic criteria and measures of clinical change. Developmental Neuropsychology 1986;2:261-76.
66. Del Sole A, Clerici F, Chiti A, Lecchi M, Mariani C, Magiore L, et al. Individual cerebral metabolic deficits in Alzheimer's disease and amnestic mild cognitive impairment: an FDG-PET study. European Journal of Nuclear Medicine and Molecular Imaging 2008;35(7):1357-66.
67. Drzezga A, Arnold S, Minoshima S, Noachtar S, Szecsi J, Winkler P, et al. 18F-FDG PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis. Journal of Nuclear Medicine 1999;40(5):737-46.
68. Duara R, Grady C, Haxby J, Sundaram M, Cutler N, Heston L, et al. Positron emission tomography in Alzheimer's disease. Neurology 1986; Vol. 36, issue 7:879-87. [0028-3878]
69. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet. Neurology 2007;6(8):734-46.
70. Dubois B, Feldman HH, Jacova C, Cummings JL, DeKosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet. Neurology 2010;9(11):1118-27. [1474-4422]
71. Fellgiebel A, Siessmeier T, Scheurich A, Winterer G, Bartenstein P, Schmidt LG, at al. Association of elevated phospho-tau levels with Alzheimer-typical 18F-Fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment. Biological Psychiatry 2004;56(4):279-83.
72. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; Vol. 366, issue 9503:2112-7. [0140-6736]
73. Frisoni GB, Bocchetta M, Chételat G, Rabinovici GD, de Leon MJ, Kaye J, et al. Imaging markers for Alzheimer disease: which vs how. Neurology 2013;81(5):487-500. [DOI: 10.1212/WNL.0b013e31829d86e8]
74. Geslani DM, Tierney MC, Herrmann N, Szalai JP. Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2005; Vol. 19, issue 5-6:383-9. [1420-8008]
75. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. National Reviews. Drug Discovery 2010;9(7):560-74.
76. Haxby JV, Grady CL, Duara R, Schlageter N, Berg G, Rapoport SI. Neocortical metabolic abnormalities precede non memory cognitive defects in early Alzheimer's-type dementia. Archives of Neurology 1986; Vol. 43, issue 9:882.
77. Herholz K, Nordberg A, Salmon E, Perani D, Kessler J, Mielke R, et al. Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 1999;10(6):494-504.
78. Herholz K, Salmon E, Perani D, Baron J, Holthoff V, Frölich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. NeuroImage 2002; Vol. 17, issue 1:302-16. [1053-8119]
79. Hoffman JM, Welsh-Bohmer KA, Hanson M, Crain B, Hulette C, Earl N, et al. FDG PET imaging in patients with pathologically verified dementia. Journal of Nuclear Medicine 2000;41(11):1920-8.
80. World Health Organization. Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10). available from apps.who.int/classifications/icd10/browse/2010/en.International (accessed 16th December 2012) 2010.
81. World Health Organization. Statistical Classification of Diseases and Related Health Problems 9th Revision (ICD-9). 6th Edition. Vol. Hospital edition, vols. 1, 2, 3, Los Angeles, CA: Practice Management Information Corporation (PMIC), 2006.
82. Ishii K, Willoch F, Minoshima S, Drzezga A, Ficaro EP, Cross DJ, et al. Statistical brain mapping of 18F-FDG PETin Alzheimer's disease: validation of anatomic standardization for atrophied brains. Journla of Nuclear Medicine 2001;42(4):548 -57.
83. Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimer's & Dementia 2010;6:221-9.
84. Jelic V, Wahlund LO, Almkvist O, Johansson SE, Shigeta M, Winblad B, Nordberg A. Diagnostic accuracies of quantitative EEG and PET in mild Alzheimer's disease. Alzheimer's Reports 1999;2(5):291-8.
85. Knopman DS, Boeve BF, Parisi JE, Dickson DW, Smith GE, Ivnik RJ. Antemortem diagnosis of frontotemporal lobar degeneration. Annals of Neurology 2005;57(4):480-8.
86. Knottnerus JA, Van Weel C, Muris JWM. Evaluation of diagnostic procedures. BMJ 2002; Vol. 324, issue 7335:477-80. [0959-8138]
87. Laforce R Jr, Buteau JP, Paquet N, Verret L, Houde M, Bouchard RW. The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: a retrospective memory clinic study. American Journal of Alzheimer's Disease and Other Dementias 2010;25(4):324-32.
88. Leeflang MMG, Deeks JJ, Gatsonis C, Bossuyt PMM. Systematic reviews of diagnostic test accuracy. Annals of Internal Medicine 2008; Vol. 149, issue 12:889.
89. Lucignani G, Frost JF. Neurochemical imaging with emission tomography: Clinical applications. link.springer.com/chapter/10.1007/3-540-30005-8_2#page-1Diagnostic nuclear medicine (accessed January 12 2015) 2006.
90. The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry 1994;57(4):416-8.
91. Matthews FE, Stephan B, McKeith IG, Bond J, Brayne C. Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. Journal of the American Geriatrics Society 2008; Vol. 56, issue 8:1424-33. [1532-5415]
92. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302(4):385-93.
93. McKeith I, Galasko D, Kosaka K, Perry E, Dickson D, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) Report of the consortium on DLB international workshop. Neurology 1996; Vol. 47, issue 5:1113-24. [0028-3878]
94. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Journal of Alzheimer's Disease 2006; Vol. 9, issue 3 Suppl:417-23. [1387-2877]
95. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34(7):939-44. [0028-3878]
96. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011;7(3):263-9. [1552-5260]
97. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI:10.1002/14651858.CD003154.pub5 ]
98. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. Journal of Nuclear Medicine 1995;36(7):1238-48.
99. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology; Neurology 1993;43(11):2412-4. [1526-632X]
100. Morris JC, Price JL. Pathologic correlates of non demented aging, mild cognitive impairment, and early-stage Alzheimer's disease. Journal of Molecular Neuroscience 2001; Vol. 17, issue 2:101-18. [0895-8696]
101. Mosconi L. FDG PET in the evaluation of mild cognitive impairment and early dementia. In: Silverman D editor(s). PET in the Evaluation of Alzheimer's Disease and Related Disorders. Springer, 2009:49-65. [0387764194]
102. Moulin-Romsee G, Maes A, Silverman D, Mortelmans L, Van Laere K. Cost-effectiveness of 18F-fluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective. European Journal of Neurology 2005;12(4):254-63.
103. National Audit Office. Improving Services and Support for People with Dementia. www.nao.org.uk/wp-content/uploads/2007/07/0607604.pdf 2007.
104. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; Vol. 51, issue 6:1546-54. [0028-3878]
105. Nitrini R, Buchpiguel C, Caramelli P, Bahia V, Mathias S, Nascimento C, et al. SPECT in Alzheimer's disease: features associated with bilateral parietotemporal hypoperfusion. Acta Neurologica Scandinavica 2000; Vol. 101, issue 3:172-6. [1600-0404]
106. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; Vol. 43, issue 3:321-32.
107. Okello A, Edison P, Archer H, Turkheimer F, Kennedy J, Bullock R, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009; Vol. 72, issue 1:56-62. [0028-3878]
108. Patterson JC, Lilien DL, Takalkar A, Pinkston JB. Early detection of brain pathology suggestive of early AD using objective evaluation of FDG-PET scans. International Journal of Alzheimer's Disease 2010; Vol. 2011:ii. 946590. [DOI:10.4061/2011/946590 ]
109. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology 1999; Vol. 56, issue 3:303-8.
110. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Archives of Neurology 2001; Vol. 58, issue 12:1985-92.
111. Petersen RC. Conceptual overview. In: Petersen RC editor(s). Mild Cognitive Impairment: Aging to Alzheimer's Disease. New York:: Oxford University Press, 2003:1-14.
112. Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine 2004; Vol. 256, issue 3:183-94. [1365-2796]
113. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, et al. Mild cognitive impairment: ten years later. Archives of Neurology 2009; Vol. 66, issue 12:1447-55.
114. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization. Neurology 2010;74(3):201-9.
115. Quinn TJ, Fearon P, Noel-Storr AH, Young C, McShane R, Stott DJ. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within community dwelling populations. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI:10.1002/14651858.CD010079 ]
116. Reisberg B, Ferris SH, De Leon MJ. Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. American Journal of Psychiatry 1982;139(9):1136-9.
117. Román GC, Tatemichi TK, Erkinjuntti T, Cummings J, Masdeu J, Garcia JH, et al. Vascular dementia diagnostic criteria for research studies: Report of the NINDS-AIREN International Workshop. Neurology 1993; Vol. 43, issue 2:250-60. [0028-3878]
118. Rosen WG, Mohs RC, Davis KL. A new rating scale forAlzheimer's disease. American Journal of Psychiatry 1984;141(11):1356-64.
119. Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Statistics in Medicine 2001; Vol. 20, issue 19:2865-84. [1097-0258]
120. Schroeter ML, Stein T, Maslowski N, Neumann J. Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta-analysis involving 1351 patients. NeuroImage 2009; Vol. 47, issue 4:1196-206. [1053-8119]
121. Silverman DH, Gambhir SS, Huang HW, Schwimmer J, Kim S, Small GW, et al. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. Journal of Nuclear Medicine 2002;43(2):253-66.
122. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 2001;286(17):2120-7.
123. Silverman DHS. Clinical interpretation of brain PET scans: performing visual assessments, providing quantifying data, and generating integrated reports. In: Silverman DHS editor(s). PET in the Evaluation of Alzheimer's Disease and Related Disorders. New York: Springer, 2009:33-49.
124. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011; Vol. 7, issue 3:280-92. [1552-5260]
125. Varrone A, Asenbaum S, Vander Borght V, Booij J, Nobili F, Någren K, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. European Journal of Nuclear Medicine and Molecular Imaging 2009;36(12):2103-10.
126. Visser PJ, Kester A, Jolles J, Verhey F. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology 2006; Vol. 67, issue 7:1201-7. [0028-3878]
127. Waxman A, Herholz K, Lewis D, Herscovitch P, Minoshima S, Ichise M, et al. Society of Nuclear Medicine procedure guideline for FDG PET brain imaging. interactive.snm.org/docs/FDG_brain_perfusion_V0%203%20(10-1)%20Final.pdf (accessed 12th January 2015) 2009.
128. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al: QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine 2011;155(8):529-36.
129. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine 2004; Vol. 256, issue 3:240-6. [1365-2796]
130. 18FDG-PET in the early diagnosis of Alzheimer's disease dementia and other dementias in people with MCI. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI:10.1002/14651858.CD010632 ]